eprintid: 14599
rev_number: 2
eprint_status: archive
userid: 1
dir: disk0/00/01/45/99
datestamp: 2023-11-10 03:29:11
lastmod: 2023-11-10 03:29:11
status_changed: 2023-11-10 01:57:19
type: article
metadata_visibility: show
creators_name: Moshikur, R.M.
creators_name: Ali, M.K.
creators_name: Wakabayashi, R.
creators_name: Moniruzzaman, M.
creators_name: Goto, M.
title: Favipiravir-Based Ionic Liquids as Potent Antiviral Drugs for Oral Delivery: Synthesis, Solubility, and Pharmacokinetic Evaluation
ispublished: pub
keywords: favipiravir; ionic liquid; amide; antivirus agent; favipiravir; ionic liquid; pyrazine derivative, animal experiment; animal tissue; area under the curve; area under the moment curve; Article; blood sampling; controlled study; differential scanning calorimetry; dissociation constant; drug accumulation; drug bioavailability; drug clearance; drug delivery system; drug formulation; drug half life; drug synthesis; elimination half-life; elimination rate constant; female; Fourier transform infrared spectroscopy; glass transition temperature; maximum concentration; mean absorption time; mean residence time; mouse; nonhuman; nuclear magnetic resonance; oral absorption; partition coefficient; phase transition; thermography; thermogravimetry; thermostability; time to maximum plasma concentration; water solubility; X ray; animal; Bagg albino mouse; chemistry; drug therapy; oral drug administration; solubility; synthesis; tissue distribution, Administration, Oral; Amides; Animals; Antiviral Agents; COVID-19; Female; Ionic Liquids; Mice; Mice, Inbred BALB C; Pyrazines; Solubility; Tissue Distribution
note: cited By 16
abstract: Coronavirus disease 2019 (COVID-19) has spread across the world, and no specific antiviral drugs have yet been approved to combat this disease. Favipiravir (FAV) is an antiviral drug that is currently in clinical trials for use against COVID-19. However, the delivery of FAV is challenging because of its limited solubility, and its formulation is difficult with common organic solvents and water. To address these issues, four FAV ionic liquids (FAV-ILs) were synthesized as potent antiviral prodrugs and were fully characterized by nuclear magnetic resonance (NMR) spectroscopy, Fourier-transform infrared (FT-IR) spectrometry, powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), derivative thermogravimetry (DTG), and differential scanning calorimetry (DSC). The aqueous solubility and in vivo pharmacokinetic properties of the FAV-ILs were also evaluated. The FAV-ILs exhibited improved aqueous solubility by 78 to 125 orders of magnitude when compared with that of free FAV. Upon oral dosing in mice, the absolute bioavailability of the β-alanine ethyl ester FAV formulation was increased 1.9-fold compared with that of the control FAV formulation. The peak blood concentration, elimination half-life, and mean absorption time of FAV were also increased by 1.5-, 2.0-, and 1.5-fold, respectively, compared with the control. Furthermore, the FAV in the FAV-ILs exhibited significantly different biodistribution compared with the control FAV formulation. Interestingly, drug accumulation in the lungs and liver was improved 1.5-fold and 1.3-fold, respectively, compared with the control FAV formulation. These results indicate that the use of ILs exhibits potential as a simple, scalable strategy to improve the solubility and oral absorption of hydrophobic drugs, such as FAV. ©
date: 2021
publisher: American Chemical Society
official_url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111211154&doi=10.1021%2facs.molpharmaceut.1c00324&partnerID=40&md5=3655612691b6b95c38cbcb4ba55e84a2
id_number: 10.1021/acs.molpharmaceut.1c00324
full_text_status: none
publication: Molecular Pharmaceutics
volume: 18
number: 8
pagerange: 3108-3115
refereed: TRUE
issn: 15438384
citation:   Moshikur, R.M. and Ali, M.K. and Wakabayashi, R. and Moniruzzaman, M. and Goto, M.  (2021) Favipiravir-Based Ionic Liquids as Potent Antiviral Drugs for Oral Delivery: Synthesis, Solubility, and Pharmacokinetic Evaluation.  Molecular Pharmaceutics, 18 (8).  pp. 3108-3115.  ISSN 15438384